Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
You may also be interested in...
Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's atopic dermatitis portfolio and provide its first biologic therapy.
Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.
Anacor Pharmaceuticals jumped 55.9% to close at $131.93 per share on 13 July on positive top-line Phase III results for the atopic dermatitis (AD) drug crisaborole, which could be safer than other topical treatments for millions of patients – mostly children – with mild-to-moderate forms of the skin disease.